ReJoin

1 stories · following the connections

Business

Cellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® Therapy

By Nasdaq OMXJan 13, 2016, 1:00 PM UTC